Ikarian Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Ikarian Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$707K	Hold	35,119	–	–	0.06%	118
2025 Q4	$567K	Buy	+35,119	New	+$465K	0.04%	135
2025 Q3	–	Sell	-198,528	Closed	-$2.74M	–	184
2025 Q2	$2.24M	Buy	+198,528	New	+$2.43M	0.43%	63
2023 Q4	–	Sell	-142,692	Closed	-$1.37M	–	159
2023 Q3	$1.37M	Buy	142,692 +2,692	+2%	+$27.5K	0.17%	91
2023 Q2	$1.26M	Hold	140,000	–	–	0.2%	80
2023 Q1	$1.1M	Buy	+140,000	New	+$1.04M	0.25%	73
2022 Q2	–	Sell	-39,730	Closed	-$586K	–	169
2022 Q1	$586K	Buy	39,730 +3,154	+9%	+$45.3K	0.08%	124
2021 Q4	$484K	Sell	36,576 -60,000	-62%	-$955K	0.07%	129
2021 Q3	$1.69M	Sell	96,576 -389	-0.4%	-$7.88K	0.12%	133
2021 Q2	$2.32M	Sell	96,965 -200,000	-67%	-$5.23M	0.19%	121
2021 Q1	$7.63M	Sell	296,965 -766,996	-72%	-$20.2M	0.26%	86
2020 Q4	$20.2M	Sell	1,063,961 -171,510	-14%	-$2.94M	0.89%	21
2020 Q3	$15.6M	Buy	1,235,471 +122,076	+11%	+$1.53M	1.13%	21
2020 Q2	$13.5M	Buy	1,113,395 +166,790	+18%	+$1.77M	1.07%	29
2020 Q1	$7.24M	Buy	946,605 +734,185	+346%	+$9.91M	0.54%	49
2019 Q4	$3.78M	Buy	+212,420	New	+$2.77M	0.61%	45

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's KALV Position: Q1 2026 in Review

Ikarian Capital held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 35,119 shares worth $707K. The position accounts for 0.06% of the portfolio, ranked #118.

Ikarian Capital first reported a position in KALV in Q4 2019 and has held it in 16 quarters since. The position peaked at $20.2M in Q4 2020. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Ikarian Capital held 35,119 shares of KalVista Pharmaceuticals worth $707K as of Q1 2026.
Ikarian Capital left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #118 holding.
Ikarian Capital first reported a position in KalVista Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
Ikarian Capital's KalVista Pharmaceuticals position peaked at $20.2M in Q4 2020.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.